Back to today’s briefing

Story perspectives

BioCryst Sues to Protect Orladeyo Patent Until 2039

3/13/2025

43 6

Summary

Story summary

BioCryst Pharmaceuticals (BCRX) has taken a bold step by filing a federal lawsuit against Annora Pharma and Hetero Labs, claiming patent infringement on its vital genetic drug, Orladeyo. This legal action aims to prevent generic versions and postpone FDA approval until 2039, safeguarding Orladeyo's critical role in treating hereditary angioedema and bolstering BCRX's anticipated sales in 2024.

1 of 1

Story summary

BioCryst Pharmaceuticals (BCRX) has taken a bold step by filing a federal lawsuit against Annora Pharma and Hetero Labs, claiming patent infringement on its vital genetic drug, Orladeyo. This legal action aims to prevent generic versions and postpone FDA approval until 2039, safeguarding Orladeyo's critical role in treating hereditary angioedema and bolstering BCRX's anticipated sales in 2024.